- $9.53bn
- $10.38bn
- $2.09bn
Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports
Brief: Qiagen Draws Early Takeover Interest From EQT, Advent - Bloomberg News
Kepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Morgan Stanley sees selective medtech opportunities on growth recovery
Europe Research Roundup: BAT, GEA Group, Qiagen
Advisory: Alerts on Qiagen N.V. withdrawn
Advisory: Alerts on Qiagen N.V. withdrawn
Brief: Qiagen Supports Infectious Disease Research And Surveillance Efforts For Bundibugyo Ebolavirus Outbreak
Brief: Pomerantz Law Firm - Investigates Claims On Behalf Of Investors Of Qiagen N.V.
Brief: Qiagen To Appoint Metin Colpan As Honorary Chairman Of The Supervisory Board
Brief: QIAGEN NV Reports Full Results For Q1 2026
DiaSorin falls as Qiagen cuts outlook on QuantiFERON weakness
Qiagen shares hit hardest day in over 5 years on outlook downgrade, weak Q1 results
Netherlands' Qiagen cuts 2026 sales and EPS outlook
Brief: Qiagen Receives U.S. Clearance For Gastrointestinal Panels On Fully Automated Qiastat-Dx Rise Syndromic Testing System
Brief: Qiagen Reports Q4 Sales USD 540 Mln
Brief: QIAGEN Appoints Mark Stevenson To Supervisory Board
Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports (updated)
Qiagen said to consider strategic options amid fresh takeover interest, Bloomberg reports